0000899243-22-008373.txt : 20220301
0000899243-22-008373.hdr.sgml : 20220301
20220301183553
ACCESSION NUMBER: 0000899243-22-008373
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220228
FILED AS OF DATE: 20220301
DATE AS OF CHANGE: 20220301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tak Paul Peter
CENTRAL INDEX KEY: 0001873905
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40629
FILM NUMBER: 22700416
MAIL ADDRESS:
STREET 1: CANDEL THERAPEUTICS, INC.
STREET 2: 117 KENDRICK ST SUITE 450
CITY: NEEDHAM
STATE: MA
ZIP: 02494
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Candel Therapeutics, Inc.
CENTRAL INDEX KEY: 0001841387
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 522214851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 117 KENDRICK STREET
STREET 2: SUITE 450
CITY: NEEDHAM
STATE: MA
ZIP: 02494
BUSINESS PHONE: 617-916-5445
MAIL ADDRESS:
STREET 1: 117 KENDRICK STREET
STREET 2: SUITE 450
CITY: NEEDHAM
STATE: MA
ZIP: 02494
FORMER COMPANY:
FORMER CONFORMED NAME: Candel Therapeutics, Inic.
DATE OF NAME CHANGE: 20210120
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-28
0
0001841387
Candel Therapeutics, Inc.
CADL
0001873905
Tak Paul Peter
C/O CANDEL THERAPEUTICS, INC.
117 KENDRICK ST., SUITE 450
NEEDHAM
MA
02494
1
1
0
0
Chief Executive Officer
Stock Option (Right to Buy)
4.12
2022-02-28
4
A
0
330000
0.00
A
2032-02-28
Common Stock
330000
330000
D
This option is subject to time-based and performance-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following the Grant Date, subject to the Reporting Person's continued service on each such vesting date; provided, however, that one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $13.50 for any ten consecutive trading days prior to or as of December 31, 2022, and an additional one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $20.00 for any ten consecutive trading days prior to or as of December 31, 2022.
/s/ John Canepa as Attorney-In-Fact for Paul Peter Tak
2022-03-01